Burnet, Michael
Synovo (Germany)
3 papers on CoChatORCID 0000-0003-4311-5441
Most cited papers
- Verified
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology
Liver Disease and TransplantationLiver physiology and pathology
Cited by 178
- Verified
The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model
Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 70
- Verified
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties
Kinzel, O., Steeneck, C., Schlüter, T., Schulz, A., Gege, C., Hahn, U., Hambruch, E., Hornberger, M., Spalwisz, A., Frick, K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters
Drug Transport and Resistance MechanismsPeroxisome Proliferator-Activated Receptors
Cited by 35
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free